Alalevonadifloxacin - CAS 706809-20-3
Catalog number: 706809-20-3
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C22H26FN3O5
Molecular Weight:
431.46
COA:
Inquire
Targets:
Antibacterials
Description:
Alalevonadifloxacin is a quinolone antibacterial. It is a DNA gyrase and DNA topoisomerase inhibitor. Alalevonadifloxacin is potentially useful to treat bacterial Gram-positive, Gram-negative and anaerobic infections. Phase II clinical trials for the treatment of Methicillin-resistant Staphylococcus aureus infections and Skin and soft tissue infections are on-going.
Purity:
98%
Appearance:
Powder
Synonyms:
WCK2349;(5S)-8-[4-(L-alanyloxy)piperidin-1-yl]-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid
Solubility:
Soluble in DMSO
Storage:
-20℃ Freezer
MSDS:
Inquire
Application:
Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
InChIKey:
OUXXDXXQNWKOIF-RYUDHWBXSA-N
InChI:
1S/C22H26FN3O5/c1-11-3-4-14-18-15(20(27)16(21(28)29)10-26(11)18)9-17(23)19(14)25-7-5-13(6-8-25)31-22(30)12(2)24/h9-13H,3-8,24H2,1-2H3,(H,28,29)/t11-,12-/m0/s1
Canonical SMILES:
C[C@H](N)C(=O)OC1CCN(CC1)c2c(F)cc3C(=O)C(=CN4[C@@H](C)CCc2c34)C(=O)O
Current Developer:
Originator Wockhardt
1.Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects.
Rodvold KA;Gotfried MH;Chugh R;Gupta M;Yeole R;Patel A;Bhatia A Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02297-17. doi: 10.1128/AAC.02297-17. Print 2018 Mar.
Alalevonadifloxacin (WCK 2349) is a novel l-alanine ester prodrug of levonadifloxacin that is being developed as an oral fluoroquinolone antibiotic. The primary objective of this study was to determine and compare plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations of levonadifloxacin following oral administration of alalevonadifloxacin to healthy adult subjects. Levonadifloxacin concentrations in plasma, ELF, and AM samples from 30 healthy subjects were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) following oral dosing of alalevonadifloxacin (1,000 mg twice daily for 5 days). Six subjects were assigned to each bronchoalveolar lavage (BAL) fluid sampling time, i.e., 2, 4, 6, 8, or 12 h after the ninth oral dose. Noncompartmental pharmacokinetic (PK) parameters were determined from serial total plasma concentrations collected over a 12-h interval following the first and ninth oral doses. Penetration ratios were calculated from the areas under the concentration-time curves from 0 to 12 h (AUC;0-12;) for plasma, ELF, and AM by using mean (and median) concentrations at each BAL sampling time. Unbound plasma concentrations (∼85% plasma protein binding) were used to determine site-to-plasma penetration ratios.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Quick Inquiry

Verification code

Featured Items